Log In Sign up
The largest database of trusted experimental protocols

Hiseq 4000 sr

Manufactured by Illumina
Visit Supplier

The HiSeq 4000 SR is a high-throughput sequencing system designed for large-scale genomic applications. The system utilizes Illumina's proprietary sequencing-by-synthesis technology to generate high-quality sequencing data. The HiSeq 4000 SR is capable of producing up to 1.5 terabases of sequencing data per run, making it suitable for a wide range of genomic research projects.

Automatically generated - may contain errors

Lab products found in correlation

Hiseq 2500, by Illumina (2 mentions) Truseq stranded total rna reagents, by Illumina (2 mentions) Hiseq pe cluster kit v4 cbot reagents, by Illumina (2 mentions) Hiseq sbs kit v4 reagents, by Illumina (2 mentions)

Spelling variants of this product

HiSeq 4000 (5649 citations) HiSeq 3000/4000 SR Cluster Kit (5 citations) HiSeq 3000/4000 SR Cluster Kit reagents (3 citations)

2 protocols using hiseq 4000 sr

1

RNA-Seq of BRCA1 Mutant Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
RNA from UWB1.289 (BRCA1 2594delCmut, BRCA1mut, n = 3) and UWB1.289 BRCA1+ (BRCA1wt; n = 3) cell lines was extracted using the RNA easy kit. RNA quality was assessed using the Fragment Analyzer. RNA sequencing libraries were prepared using the Illumina TruSeq Stranded Total RNA reagents according to the protocol supplied by the manufacturer and using 1 μg of total RNA. Cluster generation was performed with the libraries using the Illumina HiSeq PE Cluster Kit v4 cBot reagents and sequenced on the Illumina HiSeq 2500 using HiSeq SBS Kit V4 reagents.
Similarly for mouse tissues, bulk RNA was extracted from snap frozen tissues using the RNA easy kit. RNA quality was assessed using the Fragment Analyzer. RNA sequencing libraries were prepared using the Illumina TruSeq Stranded Total RNA reagents according to the protocol supplied by the manufacturer and sequenced using HiSeq 4000 SR.
Bruand M., Barras D., Mina M., Ghisoni E., Morotti M., Lanitis E., Fahr N., Desbuisson M., Grimm A., Zhang H., Chong C., Dagher J., Chee S., Tsianou T., Dorier J., Stevenson B.J., Iseli C., Ronet C., Bobisse S., Genolet R., Walton J., Bassani-Sternberg M., Kandalaft L.E., Ren B., McNeish I., Swisher E., Harari A., Delorenzi M., Ciriello G., Irving M., Rusakiewicz S., Foukas P.G., Martinon F., Dangaj Laniti D, & Coukos G. (2021). Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell reports, 36(3), 109412.
+ Open protocol
+ Expand
2

RNA-Seq of BRCA1 Mutant Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
RNA from UWB1.289 (BRCA1 2594delCmut, BRCA1mut, n = 3) and UWB1.289 BRCA1+ (BRCA1wt; n = 3) cell lines was extracted using the RNA easy kit. RNA quality was assessed using the Fragment Analyzer. RNA sequencing libraries were prepared using the Illumina TruSeq Stranded Total RNA reagents according to the protocol supplied by the manufacturer and using 1 μg of total RNA. Cluster generation was performed with the libraries using the Illumina HiSeq PE Cluster Kit v4 cBot reagents and sequenced on the Illumina HiSeq 2500 using HiSeq SBS Kit V4 reagents.
Similarly for mouse tissues, bulk RNA was extracted from snap frozen tissues using the RNA easy kit. RNA quality was assessed using the Fragment Analyzer. RNA sequencing libraries were prepared using the Illumina TruSeq Stranded Total RNA reagents according to the protocol supplied by the manufacturer and sequenced using HiSeq 4000 SR.
Bruand M., Barras D., Mina M., Ghisoni E., Morotti M., Lanitis E., Fahr N., Desbuisson M., Grimm A., Zhang H., Chong C., Dagher J., Chee S., Tsianou T., Dorier J., Stevenson B.J., Iseli C., Ronet C., Bobisse S., Genolet R., Walton J., Bassani-Sternberg M., Kandalaft L.E., Ren B., McNeish I., Swisher E., Harari A., Delorenzi M., Ciriello G., Irving M., Rusakiewicz S., Foukas P.G., Martinon F., Dangaj Laniti D, & Coukos G. (2021). Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell reports, 36(3), 109412.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!